Chief Scientific Officer Stephen Betz sold 1,035 shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) on September 10, 2024, according to a recent SEC Filing. Following this transaction, the insider now owns 68,576 shares of the company.

• Warning! GuruFocus has detected 5 Warning Signs with CRNX.

Crinetics Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Over the past year, Stephen Betz has sold a total of 40,035 shares of the company and has not made any purchases. The insider transaction history for Crinetics Pharmaceuticals Inc shows a trend with 37 insider sells and no insider buys over the past year.

On the day of the latest transaction, shares of Crinetics Pharmaceuticals Inc were trading at $51.5. This valuation brings the market cap of the company to approximately $4.1 billion.

For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, interested parties can explore further details on the GuruFocus website.

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

This article first appeared on GuruFocus.